Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review

Bibliography

• RANathan, EOMeltzer, JDerebery, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008;29:600-8
   PubMed Web of Science ®Google Scholar
• NRosario, LBielory. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11:471-6
   PubMed Web of Science ®Google Scholar
• TOzdoganoglu, MSongu. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis 2012;6:11-23
   PubMed Web of Science ®Google Scholar
• EFA Book on Respiratory Allergies. EValovirta. editor. 2011. Available from: http://www.theipcrg.org/download/attachments/689587/EFABookonRespiratoryAllergiesFINAL.pdf?version=1&modificationDate=1332965739000 [Last accessed 2 April 2014]
   Google Scholar
• DVWallace, MSDykewicz, DIBernstein, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1-84
   PubMed Web of Science ®Google Scholar
• AUzzaman, RStory. Chapter 5: allergic rhinitis. Allergy Asthma Proc 2012;33(Suppl 1):S15-18
   PubMedGoogle Scholar
• WAO White Book on Allergy 2013 Update. RPawankar, STHolgate, GWCanonica, et al. editors. 2013. Available from: http://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf [Last accessed 23 February 2015]
   Google Scholar
• JBousquet, NKhaltaev, AACruz, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• DKSur, SScandale. Treatment of allergic rhinitis. Am Fam Physician 2010;81:1440-6
   PubMed Web of Science ®Google Scholar
• MACalderon, BAlves, MJacobson, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007(1):CD001936
   PubMed Web of Science ®Google Scholar
• NErekosima, CSuarez-Cuervo, MRamanathan, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014;124:616-27
   PubMed Web of Science ®Google Scholar
• MACalderon, FESimons, HJMalling, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302-11
   PubMed Web of Science ®Google Scholar
• GWCanonica, LCox, RPawankar, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6
   PubMedGoogle Scholar
• JDretzke, AMeadows, NNovielli, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361-6
   PubMed Web of Science ®Google Scholar
• AMeadows, BKaambwa, NNovielli, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013;17:1-322
   Web of Science ®Google Scholar
• ADidier, UWahn, FHorak, et al. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol 2014;10:1309-24
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics: Oralair® 100 IR & 300 IR sublingual tablets. Stallergènes SA, 2013. Available from: http://www.stallergenes.co.uk/fileadmin/images/corporate/gallery/Documents_pdf/2010-10–Oralair_fin_MRP_RCP.pdf [Last accessed 15 April 2014]
   Google Scholar
• US Prescribing Information: Oralair® (Sweet vernal, Orchard, Perennial rye, Timothy, and Kentucky blue grass mixed pollens allergen extract) Tablet for sublingual use. Stallergènes SA, 2014. Available from: http://oralair.com/docs/ORALAIR%20Prescribing%20Information-Med%20Guide.pdf [Last accessed 11 May 2014]
   Google Scholar
• LSCox, TBCasale, ASNayak, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130:1327-34
   PubMed Web of Science ®Google Scholar
• ADidier, HJMalling, MWorm, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
   PubMed Web of Science ®Google Scholar
• ADidier, HJMalling, MWorm, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568-77
   PubMed Web of Science ®Google Scholar
• ADidier, MWorm, FHorak, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011;128:559-66
   PubMed Web of Science ®Google Scholar
• FHorak, PZieglmayer, RZieglmayer, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471-7
   PubMed Web of Science ®Google Scholar
• THLarsen, LKPoulsen, MMelac, et al. Safety and tolerability of grass pollen tablets in sublingual immunotherapy–a Phase-1 study. Allergy 2006;61:1173-6
   PubMed Web of Science ®Google Scholar
• Study NCT00803244. Safety and efficacy of Phase III study on 300 IR SLIT in patients suffering from grass pollen rhinoconjunctivitis (with or without asthma). Stallergènes SA, 2011. Available from: http://clinicaltrials.gov/show/NCT00803244 [Last accessed 20 April 2014]
   Google Scholar
• UWahn, ATabar, PKuna, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160-6
   PubMed Web of Science ®Google Scholar
• Council for International Organizations of Medical Sciences (CIOMS) Working Group III. Guidelines for preparing core clinical safety information on drugs. Geneva, Switzerland: 1995
   Google Scholar
• SMWallerstedt, GBrunlof, ASundstrom. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register. Drug Saf 2011;34:669-82
   PubMed Web of Science ®Google Scholar
• TGEpstein, GMLiss, KMurphy-Berendts, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract 2014;2:161-7
   PubMed Web of Science ®Google Scholar
• HASampson, AMunoz-Furlong, RLCampbell, et al. Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7
   Google Scholar
• KCHsiao, JSmart. Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation. Pediatr Allergy Immunol 2014;25:714-5
   PubMed Web of Science ®Google Scholar
• KALyseng-Williamson. Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. Drugs Ther Perspect 2014;10.1007/s40267-40014-40131-40267
   Google Scholar
• MMakatsori, MACalderon. Anaphylaxis: still a ghost behind allergen immunotherapy. Curr Opin Allergy Clin Immunol 2014;14:316-22
   PubMed Web of Science ®Google Scholar
• FMadsen, LFrolund, MChristensen, et al. Quality assurance of allergen-specific immunotherapy during a national outbreak of anaphylaxis: results of a continuous sentinel event surveillance system. J Investig Allergol Clin Immunol 2009;19:253-9
   PubMed Web of Science ®Google Scholar
• ALinneberg, RKJacobsen, LJespersen, et al. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129:413-9
   PubMed Web of Science ®Google Scholar
• ALinneberg, FMadsen, TSkaaby. Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 2012;12:635-9
   PubMed Web of Science ®Google Scholar